Published December 1, 2020 | Version v1
Patent Open

Conjugates of IL13Rα2 binding agents and use thereof in cancer treatment

  • 1. University of Chicago

Contributors

Patent applicant:

Description

Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13Rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13Rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).

Files

US10851169.pdf

Files (5.8 MB)

Name Size Download all
md5:af162d3e96b8526e7c7022970c24b6d4
5.8 MB Preview Download

Additional details

Identifiers

Patent number
US 10851169 B2
Patent application number
US 201916385853 A
Other
oai:uchicago.tind.io:7340

Dates

Patent filed
2019-04-16

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Medicine